For the year ending 2025-12-31, BGMS had $368K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -2,998 | -11,212 |
| Depreciation | 5 | 6 |
| Gain on deconsolidation of subsidiary | 4,947 | - |
| Stock-based compensation | 2,334 | 592 |
| Changes in lease liability | 2 | -37 |
| Accounts receivable, net | 1,257 | - |
| Inventory | 1,384 | - |
| Prepaid expenses and other assets | -4,087 | -4,472 |
| Accounts payable, accrued and other current liabilities | -10,506 | -1,811 |
| Net cash used in operating activities | -4,770 | -7,990 |
| Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net | 6,425 | 6,209 |
| Payment made under the warrant exchange amendment | 1,100 | - |
| Proceeds from the exercise of stock options and warrants, net of issuance costs | - | 1,613 |
| Payment of preferred stock dividend | 61 | - |
| Net cash provided by in financing activities | 5,264 | 7,822 |
| Effect of exchange rate changes on cash and cash equivalents | -126 | -73 |
| Net increase (decrease) in cash and cash equivalents | 368 | -241 |
| Cash and cash equivalents, beginning of period | 3,137 | 3,378 |
| Cash and cash equivalents, end of period | 3,505 | 3,137 |
Bio Green Med Solution, Inc. (BGMS)
Bio Green Med Solution, Inc. (BGMS)